openPR Logo
Press release

Investigation announced for Long-Term Investors in shares of Trevena, Inc. (NASDAQ: TRVN)

09-23-2019 09:56 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in Trevena, Inc. (NASDAQ: TRVN) shares over possible breaches of fiducia

An investigation on behalf of current long term investors in Trevena, Inc. (NASDAQ: TRVN) shares over possible breaches of fiducia

An investigation was announced for investors in shares of Trevena, Inc. (NASDAQ: TRVN) concerning potential breaches of fiduciary duties by certain directors of Trevena, Inc..

Investors who are current long term investors in Trevena, Inc. (NASDAQ: TRVN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NASDAQ: TRVN stocks follows a lawsuit filed against Trevena, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: TRVN stocks, concerns whether certain Trevena directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Eastern District of Pennsylvania the plaintiff alleges that Trevena misled its shareholders to believe that its April 28, 2016 End-of-Phase 2 Meeting with the United States Food and Drug Administration ("FDA") was far more successful than it actually was.

Those who purchased shares of Trevena, Inc. (NASDAQ: TRVN) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Long-Term Investors in shares of Trevena, Inc. (NASDAQ: TRVN) here

News-ID: 1836428 • Views: 812

More Releases from Shareholders Foundation

Investigation announced for Investors in shares of So-Young International Inc. ( …
So-Young International Inc. (NASDAQ: SY) is under investigation over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of So-Young International Inc. (NASDAQ: SY), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of So-Young International Inc. (NASDAQ: SY) concerning whether a
Investigation announced for Long-Term Investors in Cloudera, Inc. (NYSE: CLDR)
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Cloudera, Inc. (NYSE: CLDR). Investors who are current long term investors in Cloudera, Inc. (NYSE: CLDR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in Cloudera, Inc. (NYSE: CLDR stocks follows a lawsuit filed
NASDAQ: TSG Investor Notice: Investigation announced over Takeover of The Stars …
An investigation was announced concerning whether the takeover of The Stars Group Inc. is unfair to NASDAQ: TSG stockholders. Investors who purchased shares of The Stars Group Inc. (NASDAQ: TSG) and currently hold any of those NASDAQ: TSG shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain officers and directors of The Stars Group
Deadline on Oct. 14th coming up in Lawsuit filed for certain Investors in CVS He …
A deadline is coming up on October 14, 2019 in the lawsuit filed for certain investors of CVS Health Corporation (NYSE: CVS) over alleged securities laws violations by CVS Health Corporation. Investors who purchased shares of CVS Health Corporation (NYSE: CVS) have certain options and there are strict and short deadlines running. Deadline: October 14, 2019. NYSE: CVS stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for Trevena

Migraine -Pharmaceutical and Healthcare latest Analysis | Key Players Covered Am …
HTF Market Intelligence released a new research report of 231 pages on title 'Migraine - Pipeline Review, H2 2018' with detailed analysis, forecast and strategies. Request a sample report @ https://www.htfmarketreport.com/sample-report/1429046-migraine-pipeline-review-5 About Migraine :Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and
Post-Operative Pain Management Market 2023 Universal Analysis by MRFR along with …
Market Research Future, a firm which specializes in market reports related to the Healthcare sector among others, recently forecasted in its report on ‘Global Post-operative Pain Management Market Research Report- Forecast to 2023’ that the market will demonstrate an exceptional CAGR while achieving good growth rapidly in the forecast period. Global Post-operative pain management market was expected to grow at a CAGR of 5.4% during forecasted period 2017-2023. Increasing number of surgeries
Depression Disorder Treatment Key Players - 4D Pharma PLC, BioCrea GmbH, DURECT …
Depression Overview Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics. Click here for sample report @ https://www.wiseguyreports.com/sample-request/3031095-Depression-pipeline-review-h1-2018   Major Key Players: 4D Pharma PLC BioCrea GmbH DURECT Corp Eisai Co Ltd Johnson & Johnson KemPharm Inc Trevena Inc VistaGen Therapeutics
Chemotherapy Induced Peripheral Neuropathy Market Key Players – Asahi Kasei Co …
WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2018” Chemotherapy Induced Peripheral Neuropathy Overview Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy and type of chemotherapeutic agent. Click here for sample
Chemotherapy Induced Peripheral Neuropathy - Pipeline Review H2 2017
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Peripheral Neuropathy-Pipeline Review, H2 2017, provides an overview of the Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline landscape. Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy and type of chemotherapeutic agent. Get Sample Copy
Pain Management Therapeutics Market US Analysis and Forecasts To 2022
The United States market for pain management therapeutics market remains a substantial growth area for pharmaceutical companies, as they continue their efforts to maintain significant growth margins by tapping into markets of major unmet medical needs. Complete report available at http://www.marketreportsonline.com/647095.html. United States Pain Therapeutics market persists with regular developments and discoveries of new drugs addressing pain related health ailment issue. The widespread availability of drugs and the advent of new